Trial · NCT00568685
Results by group96
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 96
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in Clinical Global Impression-Attention Deficit Hyperactivity Disorder-Severity Scale (CGI-ADHD-S) Score at Days 7, 14, 42, and Last Observation Carried Forward Endpoint | Atomoxetine 0.2 mg/kg/Day | Day 7 | -0.24 | Standard Deviation 0.480 | units on a scale |
| Change From Baseline in Clinical Global Impression-Attention Deficit Hyperactivity Disorder-Severity Scale (CGI-ADHD-S) Score at Days 7, 14, 42, and Last Observation Carried Forward Endpoint | Atomoxetine 0.5 mg/kg/Day | Day 7 | -0.53 | Standard Deviation 0.612 | units on a scale |
| Change From Baseline in Clinical Global Impression-Attention Deficit Hyperactivity Disorder-Severity Scale (CGI-ADHD-S) Score at Days 7, 14, 42, and Last Observation Carried Forward Endpoint | Atomoxetine 1.2 mg/kg/Day | Day 7 | -0.30 | Standard Deviation -.036 | units on a scale |
| Change From Baseline in Clinical Global Impression-Attention Deficit Hyperactivity Disorder-Severity Scale (CGI-ADHD-S) Score at Days 7, 14, 42, and Last Observation Carried Forward Endpoint | Atomoxetine 0.2 mg/kg/Day | Day 14 | -0.73 | Standard Deviation 0.736 | units on a scale |
| Change From Baseline in Clinical Global Impression-Attention Deficit Hyperactivity Disorder-Severity Scale (CGI-ADHD-S) Score at Days 7, 14, 42, and Last Observation Carried Forward Endpoint | Atomoxetine 0.5 mg/kg/Day | Day 14 | -0.90 | Standard Deviation 0.918 | units on a scale |
| Change From Baseline in Clinical Global Impression-Attention Deficit Hyperactivity Disorder-Severity Scale (CGI-ADHD-S) Score at Days 7, 14, 42, and Last Observation Carried Forward Endpoint | Atomoxetine 1.2 mg/kg/Day | Day 14 | -0.92 | Standard Deviation 0.786 | units on a scale |
| Change From Baseline in Clinical Global Impression-Attention Deficit Hyperactivity Disorder-Severity Scale (CGI-ADHD-S) Score at Days 7, 14, 42, and Last Observation Carried Forward Endpoint | Atomoxetine 0.2 mg/kg/Day | Day 42 | -1.04 | Standard Deviation 0.729 | units on a scale |
| Change From Baseline in Clinical Global Impression-Attention Deficit Hyperactivity Disorder-Severity Scale (CGI-ADHD-S) Score at Days 7, 14, 42, and Last Observation Carried Forward Endpoint | Atomoxetine 0.5 mg/kg/Day | Day 42 | -1.30 | Standard Deviation 1.121 | units on a scale |
| Change From Baseline in Clinical Global Impression-Attention Deficit Hyperactivity Disorder-Severity Scale (CGI-ADHD-S) Score at Days 7, 14, 42, and Last Observation Carried Forward Endpoint | Atomoxetine 1.2 mg/kg/Day | Day 42 | -1.56 | Standard Deviation 1.090 | units on a scale |
| Change From Baseline in Clinical Global Impression-Attention Deficit Hyperactivity Disorder-Severity Scale (CGI-ADHD-S) Score at Days 7, 14, 42, and Last Observation Carried Forward Endpoint | Atomoxetine 0.2 mg/kg/Day | LOCF Endpoint | -0.98 | Standard Deviation 0.750 | units on a scale |
| Change From Baseline in Clinical Global Impression-Attention Deficit Hyperactivity Disorder-Severity Scale (CGI-ADHD-S) Score at Days 7, 14, 42, and Last Observation Carried Forward Endpoint | Atomoxetine 0.5 mg/kg/Day | LOCF Endpoint | -1.22 | Standard Deviation 1.119 | units on a scale |
| Change From Baseline in Clinical Global Impression-Attention Deficit Hyperactivity Disorder-Severity Scale (CGI-ADHD-S) Score at Days 7, 14, 42, and Last Observation Carried Forward Endpoint | Atomoxetine 1.2 mg/kg/Day | LOCF Endpoint | -1.54 | Standard Deviation 1.073 | units on a scale |
| Change From Baseline in Clinical Global Impression-Attention Deficit Hyperactivity Disorder-Improvement Scale (CGI-ADHD-I) Score at Days 7, 14, 42, and Last Observation Carried Forward Endpoint | Atomoxetine 0.2 mg/kg/Day | Day 7 | 3.57 | Standard Deviation 0.645 | units on a scale |
| Change From Baseline in Clinical Global Impression-Attention Deficit Hyperactivity Disorder-Improvement Scale (CGI-ADHD-I) Score at Days 7, 14, 42, and Last Observation Carried Forward Endpoint | Atomoxetine 0.5 mg/kg/Day | Day 7 | 3.22 | Standard Deviation 0.642 | units on a scale |
| Change From Baseline in Clinical Global Impression-Attention Deficit Hyperactivity Disorder-Improvement Scale (CGI-ADHD-I) Score at Days 7, 14, 42, and Last Observation Carried Forward Endpoint | Atomoxetine 1.2 mg/kg/Day | Day 7 | 3.54 | Standard Deviation 0.813 | units on a scale |
| Change From Baseline in Clinical Global Impression-Attention Deficit Hyperactivity Disorder-Improvement Scale (CGI-ADHD-I) Score at Days 7, 14, 42, and Last Observation Carried Forward Endpoint | Atomoxetine 0.2 mg/kg/Day | Day 14 | 3.25 | Standard Deviation 0.729 | units on a scale |
| Change From Baseline in Clinical Global Impression-Attention Deficit Hyperactivity Disorder-Improvement Scale (CGI-ADHD-I) Score at Days 7, 14, 42, and Last Observation Carried Forward Endpoint | Atomoxetine 0.5 mg/kg/Day | Day 14 | 3.20 | Standard Deviation 0.957 | units on a scale |
| Change From Baseline in Clinical Global Impression-Attention Deficit Hyperactivity Disorder-Improvement Scale (CGI-ADHD-I) Score at Days 7, 14, 42, and Last Observation Carried Forward Endpoint | Atomoxetine 1.2 mg/kg/Day | Day 14 | 2.98 | Standard Deviation 0.721 | units on a scale |
| Change From Baseline in Clinical Global Impression-Attention Deficit Hyperactivity Disorder-Improvement Scale (CGI-ADHD-I) Score at Days 7, 14, 42, and Last Observation Carried Forward Endpoint | Atomoxetine 0.2 mg/kg/Day | Day 42 | 3.24 | Standard Deviation 0.970 | units on a scale |
| Change From Baseline in Clinical Global Impression-Attention Deficit Hyperactivity Disorder-Improvement Scale (CGI-ADHD-I) Score at Days 7, 14, 42, and Last Observation Carried Forward Endpoint | Atomoxetine 0.5 mg/kg/Day | Day 42 | 3.09 | Standard Deviation 0.952 | units on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00568685/results